Sector Gamma AS Reduces Holdings in BioNTech SE Sponsored ADR $BNTX

Sector Gamma AS reduced its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 26.0% during the third quarter, HoldingsChannel reports. The fund owned 27,732 shares of the company’s stock after selling 9,738 shares during the quarter. Sector Gamma AS’s holdings in BioNTech were worth $2,735,000 as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in BNTX. Rhenman & Partners Asset Management AB increased its stake in shares of BioNTech by 0.3% in the second quarter. Rhenman & Partners Asset Management AB now owns 35,870 shares of the company’s stock worth $3,819,000 after purchasing an additional 120 shares in the last quarter. Kennedy Capital Management LLC lifted its stake in shares of BioNTech by 0.8% during the 2nd quarter. Kennedy Capital Management LLC now owns 16,422 shares of the company’s stock valued at $1,748,000 after buying an additional 127 shares in the last quarter. Probity Advisors Inc. boosted its holdings in BioNTech by 5.7% in the 3rd quarter. Probity Advisors Inc. now owns 2,506 shares of the company’s stock worth $247,000 after buying an additional 135 shares during the period. Profund Advisors LLC grew its stake in BioNTech by 3.6% in the 2nd quarter. Profund Advisors LLC now owns 4,309 shares of the company’s stock valued at $459,000 after buying an additional 149 shares in the last quarter. Finally, Banco Bilbao Vizcaya Argentaria S.A. raised its holdings in BioNTech by 2.5% during the 2nd quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 7,653 shares of the company’s stock valued at $822,000 after acquiring an additional 186 shares during the period. 15.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

BNTX has been the topic of a number of analyst reports. Bank of America decreased their price objective on BioNTech from $134.00 to $130.00 and set a “buy” rating on the stock in a research note on Wednesday, October 22nd. The Goldman Sachs Group upgraded BioNTech from a “neutral” rating to a “buy” rating and upped their price target for the company from $115.00 to $142.00 in a research report on Friday, January 16th. Berenberg Bank restated a “buy” rating on shares of BioNTech in a research report on Friday. TD Cowen reaffirmed a “hold” rating on shares of BioNTech in a research note on Monday, November 3rd. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $151.00 target price on shares of BioNTech in a research note on Wednesday, December 3rd. Eleven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $140.03.

BioNTech Stock Down 2.1%

Shares of NASDAQ BNTX opened at $115.98 on Friday. The company has a current ratio of 7.12, a quick ratio of 7.02 and a debt-to-equity ratio of 0.01. The business has a 50-day moving average of $99.39 and a 200-day moving average of $103.68. The firm has a market capitalization of $26.12 billion, a price-to-earnings ratio of -44.10 and a beta of 1.40. BioNTech SE Sponsored ADR has a 12 month low of $81.20 and a 12 month high of $126.77.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.75 by ($0.89). BioNTech had a negative net margin of 17.91% and a negative return on equity of 3.03%. The company had revenue of $1.78 billion for the quarter, compared to the consensus estimate of $1.21 billion. The company’s revenue for the quarter was up 22.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.81 earnings per share. Sell-side analysts expect that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.